Skip to content
Screener
PROCEPT BioRobotics Corporation logo

PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics is a surgical robotics company that develops and commercializes transformative solutions in urology, specifically for the treatment of benign prostatic hyperplasia (BPH).

Market cap
$1.11B-17.6%
Revenue$337.3M+22.7%
Net income-$109.8M-30.4%
Free cash flow-$84.9M+4.9%
EPS (diluted)-$1.94-26.0%
Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 4, 2026
Revenue$94.5MBeat by $1.7MEPS-$0.47Miss by $0.01

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$101.1M
EPS estimate-$0.39

Financials

Q2 2026

Income statement

See full
Revenue$94.5M+19.3%
Gross profit$62.4M+20.5%
Operating income-$27.4M-23.4%
Net income-$26.9M-37.2%
EPS (diluted)-$0.47-34.3%

Balance sheet

See full
Cash & equivalents$11.4M-96.3%
Total debt$77.5M-2.4%
Total equity$340.1M-11.9%
Total assets$479.4M-6.6%

Cash flow

See full
Operating cash flow-$19.3M-28.0%
CapEx$3.0M+5.4%
Free cash flow-$22.2M-24.4%

Valuation & ratios

Valuation

See full
Market cap$1.11B-17.6%
Enterprise value$1.17B—
P/S3.3×—

Profitability

See full
Gross margin64.2%0.0pp
Operating margin-33.9%+0.5pp
Net margin-32.5%+2.2pp
FCF margin-25.2%-4.6pp

Returns & leverage

See full
Return on equity-30.2%+5.2pp
Debt / equity0.2×0.0×
Current ratio6.5×-2.7×

Segments

By product

See full
Handpieces and other consumables$55.2M+12.3%
System sales and leases$32.5M—
Service$6.8M+36.1%

Competitors

By market cap

Intuitive Surgical logo
Intuitive Surgical$133.24B-14.5%
Medtronic logo
Medtronic$119.92B-0.7%
Boston Scientific logo
Boston Scientific$63.6B-56.7%
TFX
Teleflex$5.5B-1.7%
PROCEPT BioRobotics Corporation logo
PROCEPT BioRobotics Corporation$1.1B—
Apyx Medical Corporation logo
Apyx Medical Corporation$124.7M+54.8%
Microbot Medical logo
Microbot Medical$96.7M-40.3%
Accuray logo
Accuray$27.5M-84.8%

By revenue growth

Microbot Medical logo
Microbot Medical+242%
TFX
Teleflex+30.7%
PROCEPT BioRobotics Corporation logo
PROCEPT BioRobotics Corporation+22.7%
Intuitive Surgical logo
Intuitive Surgical+20.7%
Apyx Medical Corporation logo
Apyx Medical Corporation+18.2%
Boston Scientific logo
Boston Scientific+13.5%
Medtronic logo
Medtronic+9.8%

By net margin

Intuitive Surgical logo
Intuitive Surgical28.45%-0.1pp
Boston Scientific logo
Boston Scientific17.48%+4.0pp
Medtronic logo
Medtronic13.93%+0.3pp
Apyx Medical Corporation logo
Apyx Medical Corporation-16.24%+26.3pp
PROCEPT BioRobotics Corporation logo
PROCEPT BioRobotics Corporation-32.54%-1.9pp
TFX
Teleflex-45.76%-56.9pp
Microbot Medical logo
Microbot Medical-3,669.88%+6,646pp

Profile

PROCEPT BioRobotics is a surgical robotics company that develops and commercializes transformative solutions in urology, specifically for the treatment of benign prostatic hyperplasia (BPH). Its core value proposition is Aquablation therapy, an image-guided, heat-free waterjet ablation process that provides consistent, durable, and safe resection of prostate tissue independent of surgeon experience or prostate size.

Competitive position

PROCEPT holds a unique position as the provider of the only image-guided robotic waterjet therapy for BPH, competing against traditional manual resective surgeries and non-resective implants.

GeographiesUnited States, United Kingdom, Japan, European Union
Customer segmentsHealthcare Providers, Hospitals, Specialized Surgical Centers
Business modelRazor-and-blade, Capital Equipment Sales, Direct Sales
SuppliersSingle-source component suppliers, Ultrasound system manufacturers, Contract sterilization services, Third-party logistics providers
CustomersUrology departments in hospitals, Integrated Delivery Networks (IDNs), Group Purchasing Organizations (GPOs), International distribution partners
CountryUnited States of America
Listed2021
Employees626.0
CEOLarry L. Wood
SectorHealthcare
IndustryMedical - Devices
Websiteprocept-biorobotics.com
FilingsSEC EDGAR

FAQ

What is PROCEPT BioRobotics Corporation's market cap?
PROCEPT BioRobotics Corporation (PRCT) has a market capitalization of $1.1B and trades on NASDAQ.
What is PROCEPT BioRobotics Corporation's revenue and profitability?
PROCEPT BioRobotics Corporation generated $337.3M in trailing twelve-month revenue with a net loss of $109.8M, representing a net margin of -32.5%. Gross margin stands at 64.2%, with free cash flow of -$84.9M. The latest reported period is Q2 2026.
Who are PROCEPT BioRobotics Corporation's competitors?
PROCEPT BioRobotics Corporation's key competitors include Intuitive Surgical, Boston Scientific Corporation, Teleflex Incorporated, and others. These companies compete in similar markets and product categories.
Who does PROCEPT BioRobotics Corporation partner with?
PROCEPT BioRobotics Corporation's notable partners include Canadian Imperial Bank of Commerce.
Where is PROCEPT BioRobotics Corporation headquartered?
PROCEPT BioRobotics Corporation is headquartered in United States of America and employs approximately 626 people. It has been publicly traded since 2021.